Skip to main content

Real-world comparative effectiveness and persistence of ustekinumab versus vedolizumab across cohort mean age in Crohn's disease: A systematic review and meta-analysis with meta-regression

In brief

Ustekinumab had 70% higher odds of effectiveness than vedolizumab in Crohn's disease

Across real-world studies, ustekinumab was more effective than vedolizumab in Crohn's disease and also had better treatment persistence. The effectiveness advantage was not seen in cohorts with a mean age of 60 or older, but age did not significantly modify results in meta-regression; patient-level studies are needed to clarify how treatment choices should differ for older adults.

Journal
Therapeutic advances in gastroenterology (Q1)
Published
8 October 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Jong Yoon Lee, Hyun Jung Kim, Jung Won Lee, Jae Hyun Kim, Seung Min Hong, Hyun-Ji Shin, et al.
PMID
43047869
DOI
10.1177/17562848261491077

Why clinicians should know about it

  • Picked for Gastroenterology (paper of the day, 22 November 2026): Comparative real-world effectiveness of Crohn's disease biologics

Abstract

BACKGROUND: Selecting biologic therapy for older patients with inflammatory bowel disease is challenging given limited age-specific data. OBJECTIVES: We examined whether cohort mean age is associated with the comparative effectiveness and persistence of ustekinumab (UST) versus vedolizumab (VDZ). DESIGN: Systematic review and meta-analysis with meta-regression of real-world comparative studies. DATA SOURCES AND METHODS: We searched MEDLINE, Embase, Cochrane CENTRAL, and KoreaMed from inception to January 9, 2026 for real-world comparative studies reporting adjusted estimates, and synthesized 48-52 week effectiveness and persistence separately using inverse-variance random-effects models, exploring age effects by subgroup analysis and meta-regression. RESULTS: Seventeen publications comprising 18 cohorts were included, with Crohn's disease (CD) predominating and ulcerative colitis data limited. Pooled effectiveness favored UST in CD (adjusted odds ratio 1.70, 95% confidence interval 1.13-2.56) but not in the stratum with a cohort mean age of ≥60 years (0.91, 0.32-2.56), with a significant between-subgroup difference (P = 0.0038). Cohort mean age was not a significant moderator of effectiveness in meta-regression (slope -0.0393, P = 0.093; eβ 0.96 per year, 95% CI 0.92-1.01). Persistence favored UST (adjusted hazard ratio 1.59, 1.21-2.10) with no age association (P = 0.903), and biologic-naive proportion was not a significant moderator. CONCLUSION: In CD, UST was favored over VDZ for both effectiveness and persistence, and its effectiveness advantage appeared to attenuate with increasing cohort mean age. Because these are study-level data, this age-related pattern warrants confirmation through patient-level analyses and dedicated studies in older adults, in whom direct comparative evidence remains limited.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.